SI3524234T1 - Trdne oblike sofosbuvira - Google Patents
Trdne oblike sofosbuviraInfo
- Publication number
- SI3524234T1 SI3524234T1 SI201531513T SI201531513T SI3524234T1 SI 3524234 T1 SI3524234 T1 SI 3524234T1 SI 201531513 T SI201531513 T SI 201531513T SI 201531513 T SI201531513 T SI 201531513T SI 3524234 T1 SI3524234 T1 SI 3524234T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sofosbuvir
- solid state
- state forms
- forms
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1610DE2014 | 2014-06-13 | ||
EP14002279 | 2014-07-03 | ||
EP14180278 | 2014-08-07 | ||
IN2268DE2014 | 2014-08-08 | ||
US201562119599P | 2015-02-23 | 2015-02-23 | |
US201562157043P | 2015-05-05 | 2015-05-05 | |
EP15167228 | 2015-05-11 | ||
EP15167683 | 2015-05-13 | ||
IN1348DE2015 | 2015-05-14 | ||
EP15169888 | 2015-05-29 | ||
EP19154561.5A EP3524234B1 (en) | 2014-06-13 | 2015-06-12 | Solid state forms of sofosbuvir |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3524234T1 true SI3524234T1 (sl) | 2021-05-31 |
Family
ID=54832933
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531985T SI3845221T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvirja |
SI201531513T SI3524234T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
SI201530663T SI3154526T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531985T SI3845221T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvirja |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201530663T SI3154526T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
Country Status (6)
Country | Link |
---|---|
US (1) | US10214553B2 (sl) |
EP (3) | EP3524234B1 (sl) |
CA (1) | CA2988393C (sl) |
ES (1) | ES2971478T3 (sl) |
SI (3) | SI3845221T1 (sl) |
WO (2) | WO2015191945A2 (sl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
WO2017003719A2 (en) | 2015-06-30 | 2017-01-05 | 3M Innovative Properties Company | Illuminator |
US10738071B2 (en) | 2016-03-17 | 2020-08-11 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
CN106220639A (zh) * | 2016-07-22 | 2016-12-14 | 上海众强药业有限公司 | 一种维帕他韦中间体新晶型 |
CZ2016553A3 (cs) * | 2016-09-09 | 2018-03-21 | Zentiva, K.S. | Pevná farmaceutická dávková forma obsahující sofosbuvir |
CN106432253B (zh) * | 2016-09-21 | 2019-06-14 | 上海众强药业有限公司 | 一种维帕他韦新晶型及其制备方法 |
RU2656228C9 (ru) * | 2017-06-13 | 2019-04-16 | Олег Ростиславович Михайлов | Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе |
EP3661944A1 (en) | 2017-08-03 | 2020-06-10 | Sandoz AG | Sofosbuvir hydrate |
CN110693887B (zh) * | 2019-05-17 | 2022-06-17 | 歌礼药业(浙江)有限公司 | 包含索磷布韦和拉维达韦的片剂及其制备方法 |
CN111773192B (zh) * | 2020-08-18 | 2024-08-02 | 福建广生堂药业股份有限公司 | 一种索磷布韦片剂及其制备方法 |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
MX337050B (es) * | 2010-01-28 | 2016-02-10 | Riboscience Llc | Compuestos 4'-azido-nucleósidos como anti-vhc. |
EP2609923B1 (en) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
UA122959C2 (uk) | 2010-03-31 | 2021-01-27 | Гайлід Фармассет Елелсі | Нуклеозидфосфорамідати |
PE20141296A1 (es) * | 2011-11-29 | 2014-10-08 | Gilead Pharmasset Llc | Composiciones y metodos para tratar el virus de la hepatitis c |
US8889159B2 (en) * | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CN104583224A (zh) | 2012-07-03 | 2015-04-29 | 百时美施贵宝公司 | 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法 |
EP3650013A1 (en) | 2013-01-31 | 2020-05-13 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
WO2015097605A1 (en) | 2013-12-23 | 2015-07-02 | Mylan Laboratories Ltd. | Process for the preparation of sofosbuvir |
EP3107924A1 (en) * | 2014-02-20 | 2016-12-28 | ratiopharm GmbH | Solid state forms of sofosbuvir |
EP3113762A1 (en) | 2014-03-05 | 2017-01-11 | Galenicum Health S.L. | Stable pharmaceutical compositions of sofosbuvir |
RU2016142819A (ru) | 2014-04-03 | 2018-05-10 | Сандоз Аг | Твердая композиция, содержащая аморфный софосбувир |
CZ2014502A3 (cs) | 2014-07-17 | 2016-01-27 | Zentiva, K.S. | Nová forma sofosbuviru a způsob její přípravy |
CN106661074A (zh) | 2014-07-31 | 2017-05-10 | 桑多斯股份公司 | 磷酰胺的合成 |
TW201609709A (zh) | 2014-08-01 | 2016-03-16 | Hc製藥公司 | 呈晶形之索非布弗(Sofosbuvir)及其製備方法 |
CN104130302B (zh) | 2014-08-08 | 2017-02-15 | 乳源东阳光药业有限公司 | 一种核苷药物的晶型及其制备方法 |
WO2016023905A1 (en) | 2014-08-13 | 2016-02-18 | Sandoz Ag | New and efficient process for the preparation of crystalline form 6 of sofosbuvir |
WO2016023906A1 (en) | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
WO2016035006A1 (en) | 2014-09-01 | 2016-03-10 | Dr. Reddy’S Laboratories Limited | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir |
WO2016038542A2 (en) | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
WO2016055576A1 (en) | 2014-10-08 | 2016-04-14 | Sandoz Ag | High drug load tablets comprising sofosbuvir |
CN104277088A (zh) | 2014-10-29 | 2015-01-14 | 汤律进 | 索菲布韦单晶m及其制备方法和用途 |
CN106046088B (zh) | 2014-11-07 | 2018-05-15 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h3及其制备方法 |
WO2016097173A1 (en) | 2014-12-17 | 2016-06-23 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
WO2016156512A1 (en) | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
WO2016189443A2 (en) | 2015-05-23 | 2016-12-01 | Virupaksha Organics Limited | Solid forms of nucleoside phosphoramidate |
US10738071B2 (en) | 2016-03-17 | 2020-08-11 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
-
2015
- 2015-06-12 WO PCT/US2015/035457 patent/WO2015191945A2/en active Application Filing
- 2015-06-12 CA CA2988393A patent/CA2988393C/en active Active
- 2015-06-12 SI SI201531985T patent/SI3845221T1/sl unknown
- 2015-06-12 EP EP19154561.5A patent/EP3524234B1/en active Active
- 2015-06-12 ES ES20212270T patent/ES2971478T3/es active Active
- 2015-06-12 SI SI201531513T patent/SI3524234T1/sl unknown
- 2015-06-12 SI SI201530663T patent/SI3154526T1/sl unknown
- 2015-06-12 EP EP20212270.1A patent/EP3845221B1/en active Active
- 2015-06-12 US US15/318,385 patent/US10214553B2/en active Active
- 2015-06-12 WO PCT/EP2015/063163 patent/WO2015189386A1/en active Application Filing
- 2015-06-12 EP EP15733573.8A patent/EP3154526B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2971478T3 (es) | 2024-06-05 |
WO2015191945A3 (en) | 2016-04-07 |
WO2015189386A1 (en) | 2015-12-17 |
EP3154526B1 (en) | 2019-03-06 |
US10214553B2 (en) | 2019-02-26 |
EP3524234A1 (en) | 2019-08-14 |
US20170137453A1 (en) | 2017-05-18 |
CA2988393C (en) | 2023-08-22 |
SI3154526T1 (sl) | 2019-08-30 |
WO2015191945A2 (en) | 2015-12-17 |
EP3845221A1 (en) | 2021-07-07 |
CA2988393A1 (en) | 2015-12-17 |
EP3845221B1 (en) | 2023-12-13 |
EP3154526A2 (en) | 2017-04-19 |
SI3845221T1 (sl) | 2024-03-29 |
EP3524234B1 (en) | 2020-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250511A0 (en) | Crystalline forms of ibrutinib | |
IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
SG11201609265RA (en) | Characterizing states of subject | |
IL257026A (en) | Solid state forms of eluxadoline | |
SI3154526T1 (sl) | Trdne oblike sofosbuvira | |
IL265628A (en) | Solid state forms of valbenazine | |
IL246979A0 (en) | Crystalline forms of sofosbuvir | |
ZA201706282B (en) | Solid forms of menaquinols | |
PL3113773T3 (pl) | Krystaliczne postaci grapiprantu | |
ZA201608686B (en) | Interseparation of metals | |
HK1223624A1 (zh) | 替諾福韋的固體形式 | |
IL249130B (en) | Preparation of piperidine-4-carbothioamide | |
IL254666A0 (en) | Crystalline forms of Aldecalcitol | |
IL249332A0 (en) | Crystalline forms of sofosbuvir | |
GB201418230D0 (en) | Construction of surfaces | |
GB201418773D0 (en) | Mechanism of action | |
GB201405155D0 (en) | Theory of entertainment | |
GB201413138D0 (en) | Assessment of structures | |
GB201413139D0 (en) | Assessment of structures | |
GB201402924D0 (en) | The theory of instantransmission | |
IL234315A0 (en) | best wishes | |
TWM489230U (en) | Improved structure of pin set | |
HUP1400294A2 (hu) | Clopidogrel új alkalmazása | |
GB201412359D0 (en) | Composition of objects |